EV/EBITDA Multiple: BioAge Labs Inc. (BIOA)

Corporate company logo of bioagelabs.com (BIOA)

The BioAge Labs, Inc. (BIOA) price chart illustrates the EV/EBITDA dynamics, which currently stands at 0.00, amid expectations regarding the results of phase two combination therapy trials. BioAge Labs, Inc. (BIOA) is developing an anti-aging system by leveraging big data analysis to identify treatment pathways for metabolic disorders. However, the business faces a lack of sales and a reliance on external financing amidst high uncertainty.

BIOA (BioAge Labs) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 11/12/2026

bioagelabs.com (BIOA) - metric breakdowns and financial figures

- market price and analyst price targets:
Price Chart BioAge Labs Inc.|BIOA - Consensus Target
- company stock exchange capitalization indicators:
Market Capitalization BioAge Labs, Inc|BIOA - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share BioAge Labs, Inc.|BIOA - Total Net Assets|Market Capitalization to Book Value Ratio bioagelabs.com|BIOA - Company Total Assets
- debt and liquidity data:
Total Debt to Capital BioAge Labs, Inc.|BIOA - Long-Term Debt to Equity|Short-Term Debt to Equity BioAge|BIOA - Company Cumulative Debt|Debt to Book Capitalization Ratio BioAge Labs, Inc|BIOA - Company Long-Term Debt|Company Short-Term Debts BioAge Labs, Inc.|Quick Liquidity bioagelabs.com
- net income and valuation multiples indicators:
BIOA - Net Financial Result|Expected Profit BioAge Labs, Inc.|BIOA - Price to Earnings Ratio|Forward P/E Multiple BioAge Labs, Inc.|BIOA - Price/Earnings to Growth Ratio|EV/EBITDA Multiple BioAge Labs, Inc|BIOA - Operating income before deduction of amortization|Earnings per share for the last twelve months BioAge Labs, Inc.|BIOA - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth bioagelabs.com|BIOA - Earnings growth in current year|Earnings growth forecast for next year BioAge Labs, Inc.
Initial company analysis:BIOA (BioAge Labs Inc.)
Product sample of BioAge

The EV/EBITDA ratio measures business value relative to operating profit before depreciation, taxes, and interest. For BioAge Labs, Inc. (BIOA), the risk of clinical trial failure makes the company's EV/EBITDA ratio on this chart an indicator of market expectations in the absence of current revenues. High values here reflect a premium for future scientific breakthroughs. An excessive gap between price and actual cash flow increases the risk of capital impairment.

Who BioAge Labs, Inc. competes with

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascendis Pharma Inc. ASND|MDGL - Enterprise Value to EBITDA Ratio|Corcept Therapeutics - EV/EBITDA Multiple|Company Value to EBITDA rhythmtx.com|AKRO (Akero) - Enterprise Value to EBITDA Ratio|MTSR: Enterprise Value to Operating Income Before Depreciation Ratio|MLTX (MoonLake Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Crinetics Corp|EV/EBITDA Multiple NAMS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SLNO (soleno.life)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Amicus Therapeutics, Inc. FOLD|89bio Inc (ETNB) - Company Value to EBITDA|AGIO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GPCR: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDXG: EV/EBITDA Multiple|RZLT - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexicon Pharmaceuticals, Inc.|MBX Biosciences, Inc. (MBX) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Altimmune Corp (ALT)|Enterprise Value to EBITDA Ratio Aardvark Pharma AARD|EV/EBITDA Multiple SGMT (Sagimet Biosciences)|biomeafusion.com - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Quince - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Fractyl Health Inc. GUTS|vtvtherapeutics.com (VTVT) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Agape ATP (ATPC)|PLUR (Pluristem Therapeutics) - EV/EBITDA Multiple|EV/EBITDA Multiple Synlogic Corp|EV/EBITDA Multiple LPCN|matinasbiopharma.com (MTNB) - Enterprise Value to EBITDA Multiple|EV/EBITDA Multiple SPRB (Spruce Biosciences)|Galecto Corporation (GLTO) - Company Value to EBITDA|CTCX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation LUMO (lumos-pharma.com)|Organovo (ONVO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RDUS (Radius Recycling Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization